Ionis Pharmaceuticals Inc
(NAS:IONS)
$
35.91
-0.42 (-1.16%)
Market Cap: 5.74 Bil
Enterprise Value: 4.73 Bil
PE Ratio: 0
PB Ratio: 8.65
GF Score: 40/100 Ionis Pharmaceuticals Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 18, 2020 / 04:35PM GMT
Release Date Price:
$51.39
(+0.19%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Good afternoon and good evening, everybody. Thanks for joining us for our final company presenter at the BofA Global Healthcare Conference. My name is Jason Gerberry, smid-cap biotech analyst at BofA. And I'm pleased to be introducing Ionis and Brett Monia, CEO of Ionis.
And Ionis, for those of you on the line who don't know, is a leader in antisense oligonucleotide therapeutics, or ASOs as we may refer to them on the call. So first off, Brett, thanks for joining us.
Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Thank you, Jason. It's a pleasure to be here.
Questions & Answers
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Yes. So hopefully next year, we'll actually be in London, but maybe we can just start big picture. And I think it's timely, given you'll have updates in the fourth quarter around new dosage form, or say new routes of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot